Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinomaWataru Fukuokaya, Shin Egawa, Yu Oyama et al.|Cancer Immunology Immunotherapy|2021Cited by 11
Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial CarcinomaWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|Targeted Oncology|2021Cited by 6
Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumabWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|British Journal of Urology|2020Cited by 6
Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI scoreYuya Iwamoto, Takahiro Kimura, Halle Foss et al.|Urologic Oncology Seminars and Original Investigations|2025Cited by 5
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative studyShuhei Hara, Fumihiko Urabe, Kojiro Tashiro et al.|Japanese Journal of Clinical Oncology|2024Cited by 4